Valuation: Black Diamond Therapeutics, Inc.

Market Cap 103M 89.76M 82.85M 76.31M 144M 9.87B 147M 988M 389M 4.83B 385M 377M 16.67B P/E 2026 *
-2.76x
P/E 2027 * -1.78x
Enterprise Value 103M 89.76M 82.85M 76.31M 144M 9.87B 147M 988M 389M 4.83B 385M 377M 16.67B EV / Sales 2026 *
18.5x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 15/09/2023
Chief Tech/Sci/R&D Officer 51 10/08/2021
Director of Finance/CFO 41 06/10/2024
Director TitleAgeSince
Director/Board Member 61 28/02/2017
Director/Board Member 47 30/11/2019
Director/Board Member 49 30/11/2018
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 103M
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.50%-2.62%+40.54%+184.05% 25.95B
Weighted average by Cap. -2.80%-2.36%+39.55%+143.13%

Financials

2026 *2027 *
Net sales 5.56M 4.86M 4.49M 4.13M 7.79M 535M 7.98M 53.54M 21.06M 261M 20.86M 20.4M 903M -
Net income -40.47M -35.42M -32.69M -30.11M -56.73M -3.9B -58.12M -390M -153M -1.91B -152M -149M -6.58B -70.04M -61.3M -56.58M -52.11M -98.18M -6.74B -101M -675M -265M -3.3B -263M -257M -11.39B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.790USD
Average target price
9.857USD
Spread / Average Target
+450.68%

Quarterly revenue - Rate of surprise